About Martin S. Masar, III, PhD
Dr. Martin Masar litigates disputes requiring advanced knowledge in the scientific fields of chemistry, the pharmaceutical arts, nanotechnology and biotechnology, especially related to intellectual property rights. He regularly advises clients on matters involving pharmaceutical and cosmetic products, including Hatch-Waxman Act litigation, where he has substantial trial experience. He also provided intellectual property prosecution, opinion work, due diligence and counseling. Finally, Marty also has experience in antitrust litigation.
Diverse scientific knowledge and litigation experience
In addition to his extensive Hatch-Waxman work, Marty has also been involved in patent, trademark, antitrust and unfair competition disputes related to pharmaceutical, cosmetic and consumer products. His work extends to other scientific subject matter as well; he has litigated cases involving electrical engineering, computer engineering and software. Those cases have involved, for example, fighter pilot heads-up displays, security-camera monitoring software, run-tracking apps and web-security software.
Marty has prosecuted patent applications for clients from an array of technical fields, including topical skin creams for therapeutic uses, nanotechnology-based mass spectrometry methods and apparatus, nanotechnology-based computer chip coolers, radiation therapy methods for cancer treatment, breathable polymers, fire-detection systems, medicine-dispensing systems and methods, and dietary supplements.
As part of his doctoral studies, Marty worked with Professor Chad A. Mirkin at Northwestern University. His dissertation research related to the synthesis and development of protein mimics that were useful in catalysis and sensing applications. His work led to six publications in peer-reviewed technical journals, including Journal of the American Chemical Society and Accounts of Chemical Research. Marty received one of the 100 annual fellowships from the Multidisciplinary University Research Initiative (MURI), a division of the US Department of Defense. In law school, Marty was on law review and graduated in the top 5% of his class, while also receiving numerous CALI awards for best marks in both intellectual property and legal writing classes, among others.
- Pharmaceutical and life sciences litigation
- Patent litigation
- Intellectual property litigation
- Antitrust and unfair competition litigation
- Represented Apotex, Inc. in a case involving a generic version of the billion-dollar-a-year narcolepsy drug Provigil. Applying the stringent Therasense standard for inequitable conduct, the court found that Apotex proved inequitable conduct by clear and convincing evidence. The court also found the patent invalid and that Apotex's proposed product did not infringe. This ruling opened the door for Apotex's antitrust claims, which are still being litigated.
- Represented Apotex, Inc. in patent infringement case relating to its proposed generic version of linezolid tablets, an antibiotic.
- Defended Apotex, Inc. against alleged infringement of Alcon's patents on a generic version of the eyedrop Patanol. Proved that most of the asserted patent claims were obvious.
- Represented a pharmaceutical corporation in (modafinil) patent litigation in the US District Court for the Eastern District of Pennsylvania. Issues of infringement, invalidity and unenforceability were resolved in client’s favor.
- Represent pharmaceutical company in patent infringement action asserting claims to certain methods for the manufacturing process for a stable form of quinapril magnesium.
- Defended manufacturing conglomerate against claims that it monopolized or attempted to monopolize the sale of disposable training pants.
Modern Regulatory Frameworks for the Use of Genetic and Epigenetic Underwriting Technology in Life InsuranceJanuary 4, 2021
FDA Reduces Regulatory Uncertainty with New Finalized Rule Defining "Biological Product" under BPCIA to Include Insulin and Other "Protein"-Based ProductsFebruary 28, 2020
Federal Circuit Issues Opinion on "Inherent Obviousness" in Patent Claim, Invalidating Orange Book Listed Pharma PatentJanuary 23, 2020
May 22, 2017
April 10, 2017
March 8, 2017
U.S. Supreme Court Alters Standard for Design Patent Damages and Takes Apple's $400 Million Victory Over Samsung Away (At Least for Now)December 7, 2016
June 15, 2016
- View All Publications
Presentations and Events
PresenterAugust 20, 2015